PBS listing triggered pandemic milestone with out-of-pocket costs

A major consequence of the federal government's decision to list LAGEVRIO (molnupiravir) on the PBS is that it became the first COVID-19 vaccine or treatment associated with lawful out-of-pocket patient costs. …